@inproceedings{bbadc56732104901a83469571978a515,
title = "DNA microarray in search of new drug targets for myasthenia gravis",
abstract = "DNA microarray technology was used to identify new potential drug targets for myasthenia gravis (MG), to delineate genes involved in the pathogenesis of the disease and to possibly target their protein products for immunotherapy. In this study we compared the gene expression in lymph node cells (LNC) and muscles of rats with experimental autoimmune MG (EAMG) to those of control, healthy rats. Of the genes that were found to be deregulated in EAMG, we chose to elaborate on two gene systems: (a) The chemokine IFN-γ-inducible protein 10 (IP-10, CXCL10), and its receptor (CXCR3) and (b) phosphodiesterases.",
keywords = "Autoimmunity, Chemokines, Combined therapy, DNA microarray, Myasthenia gravis, Phosphodiesterase",
author = "Tali Feferman and Revital Aricha and Renuka Menon and Souroujon, {Miriam C.} and Sonia Berrih-Aknin and Sara Fuchs",
note = "Copyright: Copyright 2018 Elsevier B.V., All rights reserved.",
year = "2007",
month = jun,
doi = "10.1196/annals.1381.012",
language = "אנגלית",
isbn = "1573316628",
series = "Annals of the New York Academy of Sciences",
publisher = "Blackwell Publishing Inc.",
pages = "111--117",
booktitle = "Autoimmunity, Part C The Mosaic of Autoimmunity",
}